Malignant Mesothelioma Market
- Malignant mesothelioma is a rare growth of mesothelial cells strongly associated with asbestos exposure. Mesothelial cells form the lining layers of the viscera. Mesothelioma can occur at any mesothelial layer such as the peritoneum or pericardium.
- There are mainly four types of mesothelioma based on location - pleural, peritoneal, pericardial, and testicular, out of which pleural mesothelioma is the most common.
- There are also three types of mesothelioma based on the cell types; epithelioid, sarcomatoid, and biphasic. The epithelioid type is associated with better outcomes. The tumor is often multifocal, forming multiple nodules starting with the parietal pleura.
- According to the findings, the age-standardized rate of mesothelioma was 0.30 per 100,000 persons with Northern Europe reporting the highest incidence rates. The incidence rate of the male population was much higher than that of the females.
- Mesothelioma is fairly rare in the United States with about 3,000 new cases each year.
- The only US FDA approved therapy currently is, Bristol Myers Squibb’s YERVOY (ipilimumab) in combination OPDIVO (nivolumab).
- The current pipeline for the treatment of malignant mesothelioma includes potential candidates like- PrE0506, and combination therapies like volrustomig + carboplatin + pemetrexed by PrECOG and Astrazeneca.
DelveInsight's “Malignant mesothelioma – Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the indication malignant mesothelioma , historical and forecasted epidemiology as well as the malignant mesothelioma market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
The malignant mesothelioma market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM malignant mesothelioma market size from 2020 to 2034. The report also covers current malignant mesothelioma treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.
Geography Covered
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
|
Study Period |
2020–2034 |
|
Forecast Period |
2024–2034 |
|
Geographies Covered |
US, EU4 (Germany, France, Italy, and Spain) the UK, and Japan |
|
Malignant mesothelioma Epidemiology
|
Segmented by:
|
|
Malignant mesothelioma key companies |
● Bristol Myers Squibb ● PrECOG ● Astrazeneca |
|
Malignant mesothelioma key therapies/drug |
● YERVOY (ipilimumab) ● OPDIVO (nivolumab) ● Volrustomig (MEDI5752) ● PrE0505/PrE0506 |
|
Malignant mesothelioma Market |
Segmented by:
|
|
Analysis |
|
Malignant Mesothelioma Understanding and Treatment Algorithm
Malignant Mesothelioma Overview, Country-Specific Treatment Guidelines and Diagnosis
Malignant mesothelioma is a rare growth of mesothelial cells strongly associated with asbestos exposure. Mesothelial cells form the lining layers of the viscera. Mesothelioma can occur at any mesothelial layer such as the peritoneum or pericardium. The pleural layer is by far the most commonly affected, giving rise to malignant pleural mesothelioma.
Malignant pleural mesothelioma is primarily linked to asbestos exposure, with some suggesting that asbestos inhalation causes repeated pleural inflammation, interference with mitosis, activation of proto-oncogenes, and free radical production.
The evaluation includes a thorax CT scan with intravenous contrast, a thoracoscopic pleural biopsy, and thoracentesis of pleural effusion, if present, with cytologic analysis.
The malignant mesothelioma report provides an overview of malignant mesothelioma pathophysiology, diagnostic approaches, and detailed treatment algorithm along with a real-world scenario of a patient’s journey beginning from the first symptom, the time taken for diagnosis to the entire treatment process.
Further details related to country-based variations in diagnosis are provided in the report..
Malignant Mesothelioma Treatment
Surgery
- Wide local excision is surgery to remove the cancer and some of the healthy tissue around it. The amount of healthy tissue removed depends on how deep or how large the tumor being removed is.
- Pleurectomy and decortication is surgery to remove part of the covering of the lungs and lining of the chest and part of the outside surface of the lungs.
- Extrapleural pneumonectomy is surgery to remove one whole lung and part of the lining of the chest, the diaphragm, and the lining of the sac around the heart.
Radition therapy
- Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing.
Chemotherapy
- Chemotherapy uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Note: Treatment therapies will be detailed in the report.
Malignant Mesothelioma Epidemiology
The Malignant mesothelioma epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2034. The malignant mesothelioma epidemiology is segmented with detailed insights into Total Incident Cases, Total Diagnosed Cases, Gender-specific Cases, Age-specific Cases, Stage-specific Cases, and Total Treated Cases of Malignant mesothelioma in the 7MM [2020-2034].
- According to the findings, in the US, the age-adjusted incidence rate (IR) for males aged 50–54 is 0.6 per 100,000, while for females it is 0.4 per 100,000.
- According to the findings the UK, records around 2,700 new mesothelioma cases every year.
- Age-related patterns of malignant mesothelioma incidence in Europe show a significant increase with age. For males aged 50–54 years, the incidence rate (IR) is 1.4 per 100,000, while for females of the same age group, the IR is 0.6 per 100,000.
Malignant Mesothelioma Recent Developments
- In October 2025, Vivace Therapeutics received FDA Fast Track Designation for VT3989, a TEAD autopalmitoylation inhibitor, for the treatment of unresectable malignant nonpleural or pleural mesothelioma after progression on immune checkpoint inhibitors and platinum-based chemotherapy. The designation supports faster development of this first-in-class Hippo pathway-targeting therapy.
Malignant Mesothelioma Drug Chapters
The drug chapter segment of the malignant mesothelioma report encloses a detailed analysis of malignant mesothelioma marketed drugs. It also deep dives into the malignant mesothelioma pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.
Marketed Drugs
YERVOY (ipilimumab) + OPDIVO (nivolumab): Bristol Myers Squibb
Ipilimumab (YERVOY): Ipilimumab is a monoclonal antibody that targets CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4). CTLA-4 is a protein receptor that downregulates the immune system. By inhibiting CTLA-4, ipilimumab enhances the immune response against cancer cells. Nivolumab (OPDIVO): Nivolumab is a monoclonal antibody that targets PD-1 (Programmed Death-1) receptor on T-cells. Blocking PD-1 enhances the body's ability to detect and destroy cancer cells.
In October 2020, the combination of YERVOY and OPDIVO was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).
Note: Detailed current therapies assessment will be provided in the full report of Malignant mesothelioma.
Emerging Therapies
PrE0505/ PrE0506: PrECOG
PrE0505 combines durvalumab, an anti-PD-L1 immunotherapy, with platinum-based chemotherapy (pemetrexed and cisplatin or carboplatin). Durvalumab blocks the interaction between PD-L1 and PD-1, enhancing the immune system's ability to detect and destroy cancer cells. The chemotherapy works by damaging the DNA of cancer cells, leading to cell death. Similar to PrE0505, the PrE0506 trial uses durvalumab in combination with platinum-based chemotherapy. The combination aims to enhance the immune response against cancer cells while directly targeting and killing the cells through chemotherapy.
PrE0505 is currently in Phase II clinical trials and PrE0506 is currently in Phase III (DREAM3R Trial) clinical trials.
Volrustomig: Astrazeneca
Volrustomig (MEDI5752 + carboplatin + pemetrexed) is an emerging combination therapy being developed by AstraZeneca for the treatment of malignant mesothelioma. MEDI5752 is designed to target specific cancer cell markers, enhancing the immune system's ability to recognize and attack malignant cells. It may also block signals that allow cancer cells to evade immune detection.
|
Emerging Drugs | ||||||
|
Drug Name |
Company |
Indications |
MoA |
RoA |
Phase |
Designations |
|
PrE0505/ PrE0506 |
PrECOG |
Malignant mesothelioma |
Anti-PD-L1 immunotherapy |
IV |
II/III |
NA |
|
Volrustomig (MEDI5752 + carboplatin + pemetrexed) |
Astrazeneca |
Malignant mesothelioma |
Immune modulation and apoptosis |
IV |
III |
NA |
Malignant Mesothelioma Market Outlook
- The market size of malignant mesothelioma in the seven major markets is expected to increase substantially during the forecast period 2024-3034.
- Increasing global prevalence of malignant mesothelioma due to historical asbestos exposure, with cases expected to rise in regions with less stringent asbestos regulations.
- Improved diagnostic techniques, including imaging and biomarkers, leading to earlier and more accurate detection.
- Development of novel therapies, such as immunotherapies and targeted therapies, enhancing treatment options and patient outcomes.
- Enhanced awareness and education efforts about mesothelioma risks, particularly among high-risk populations.
Malignant Mesothelioma Drugs Uptake
- We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.
- Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
- In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.
- Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Scope of the Report
- The report covers a segment of key events, an executive summary, descriptive overview of malignant mesothelioma , explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country specific treatment guidelines.
- Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
- A detailed review of the malignant mesothelioma market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM malignant mesothelioma .
Malignant mesothelioma Report Insights
- Patient Population
- Therapeutic Approaches
- Malignant mesothelioma Pipeline Analysis
- Malignant mesothelioma Market Size and Trends
- Existing and future Market Opportunity
- 11 Years Forecast
- 7MM Coverage
- Malignant mesothelioma Epidemiology Segmentation
- Inclusion of Country specific treatment guidelines
- KOL’s feedback on approved and emerging therapies
- Key Cross Competition
- Conjoint analysis
- Drugs Uptake and Key Market Forecast Assumptions
Malignant mesothelioma Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Qualitative Analysis (SWOT and Conjoint Analysis)
- What is the growth rate of the 7MM malignant mesothelioma treatment market?
- What was the malignant mesothelioma total market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors/key catalysts for this growth?
- Is there any unexplored patient setting that can open the window for growth in the future?
- What are the pricing variations among different geographies for approved and off-label therapies?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
- What are the current and emerging options for the treatment of malignant mesothelioma ?
- How many companies are developing therapies for the treatment of malignant mesothelioma ?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
- Patient acceptability in terms of preferred treatment options as per real-world scenarios?
- What are the country-specific accessibility issues of expensive, recently approved therapies?
- The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the malignant mesothelioma Market.
- Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
- Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
- Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
- Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
- Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
- To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
- Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
